Chagas disease and transfusion medicine: a perspective from non-endemic countries.

In the last decades, increasing international migration and travel from Latin America to Europe have favoured the emergence of tropical diseases outside their "historical" boundaries. Chagas disease, a zoonosis endemic in rural areas of Central and South America represents a clear example of this phenomenon. In the absence of the vector, one of the potential modes of transmission of Chagas disease in non-endemic regions is through blood and blood products. As most patients with Chagas disease are asymptomatic and unaware of their condition, in case of blood donation they can inadvertently represent a serious threat to the safety of the blood supply in non-endemic areas. Since the first cases of transfusion-transmitted Chagas disease were described in the last years, non-endemic countries began to develop ad hoc strategies to prevent and control the spread of the infection. United States, Spain, United Kingdom and France first recognised the need for Trypanosoma cruzi screening in at-risk blood donors. In this review, we trace an up-to-date perspective on Chagas disease, describing its peculiar features, from epidemiological, pathological, clinical and diagnostic points of view. Moreover, we describe the possible transmission of Chagas disease through blood or blood products and the current strategies for its control, focusing on non-endemic areas.

[1]  P. Buekens,et al.  Congenital Chagas disease: an update , 2015, Memorias do Instituto Oswaldo Cruz.

[2]  P. Chiodini,et al.  Health Policies to Control Chagas Disease Transmission in European Countries , 2014, PLoS neglected tropical diseases.

[3]  J. M. Rubio,et al.  The efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets , 2014, Transfusion.

[4]  Fernando Salvador,et al.  Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. , 2014, The New England journal of medicine.

[5]  M. Ndao,et al.  Evaluation of selective screening of donors for antibody to Trypanosoma cruzi: seroprevalence of donors who answer “no” to risk questions , 2014, Transfusion.

[6]  Maria Elena Bottazzi,et al.  An Unfolding Tragedy of Chagas Disease in North America , 2013, PLoS neglected tropical diseases.

[7]  G. Girelli,et al.  Surveillance of Chagas disease among at-risk blood donors in Italy: preliminary results from Umberto I Polyclinic in Rome. , 2013, Blood transfusion = Trasfusione del sangue.

[8]  M. Ndao,et al.  Selective testing for Trypanosoma cruzi: the first year after implementation at Canadian Blood Services , 2013, Transfusion.

[9]  D. Kessler,et al.  Results of lookback for Chagas disease since the inception of donor screening at New York Blood Center , 2013, Transfusion.

[10]  R. Goodrich,et al.  Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion‐associated graft‐versus‐host disease? , 2013, Transfusion.

[11]  P. Chiodini,et al.  The early implementation of Trypanosoma cruzi antibody screening of donors and donations within England: preempting a problem , 2012, Transfusion.

[12]  S. Montgomery,et al.  The United States Trypanosoma cruzi Infection Study: evidence for vector‐borne transmission of the parasite that causes Chagas disease among United States blood donors , 2012, Transfusion.

[13]  S. Weisenberg,et al.  Seroprevalence of Chagas Infection in the Donor Population , 2012, PLoS neglected tropical diseases.

[14]  M. Shikanai-Yasuda,et al.  Oral transmission of Chagas disease. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  R. Goodrich,et al.  Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood , 2012, Transfusion.

[16]  G. Russomando,et al.  Congenital Chagas Disease: Recommendations for Diagnosis, Treatment and Control of Newborns, Siblings and Pregnant Women , 2011, PLoS neglected tropical diseases.

[17]  P. Chiodini,et al.  Chagas disease in European countries: the challenge of a surveillance system. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[18]  E. Bonifacio,et al.  Chagas disease in Italy: breaking an epidemiological silence. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[19]  M. Segovia,et al.  Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country. , 2011, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[20]  R. López-Vélez,et al.  Chagas disease in Latin American migrants: a Spanish challenge. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[21]  D. Boykin,et al.  In vitro trypanocidal activity of DB745B and other novel arylimidamides against Trypanosoma cruzi. , 2011, The Journal of antimicrobial chemotherapy.

[22]  M. Ison,et al.  Screening and Treatment of Chagas Disease in Organ Transplant Recipients in the United States: Recommendations from the Chagas in Transplant Working Group , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  A. Hasslocher-Moreno,et al.  ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis , 2010, BMC infectious diseases.

[24]  B. Custer,et al.  Cost‐effectiveness of screening the US blood supply for Trypanosoma cruzi , 2010, Transfusion.

[25]  S. Wendel Transfusion transmitted Chagas disease: is it really under control? , 2010, Acta tropica.

[26]  Z. Yadón,et al.  Chagas disease: a Latin American health problem becoming a world health problem. , 2010, Acta tropica.

[27]  J. Gascón,et al.  Chagas disease and stroke , 2010, The Lancet Neurology.

[28]  J. Sztajzel,et al.  Prevalence, Clinical Staging and Risk for Blood-Borne Transmission of Chagas Disease among Latin American Migrants in Geneva, Switzerland , 2010, PLoS neglected tropical diseases.

[29]  R. López-Vélez,et al.  Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. , 2009, The Journal of antimicrobial chemotherapy.

[30]  S. Yusuf,et al.  The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. , 2009, Memorias do Instituto Oswaldo Cruz.

[31]  Anita Sands,et al.  WHO comparative evaluation of serologic assays for Chagas disease , 2009, Transfusion.

[32]  E. Castro Chagas’ disease: lessons from routine donation testing , 2009, Transfusion medicine.

[33]  D. Grana,et al.  Chagas cardiomyopathy: Europe is not spared! , 2008, European heart journal.

[34]  S. Montgomery,et al.  Chagas disease and the US blood supply , 2008, Current opinion in infectious diseases.

[35]  S. Sauleda,et al.  Seroprevalence of Trypanosoma cruzi infection in at‐risk blood donors in Catalonia (Spain) , 2008, Transfusion.

[36]  Maria Elena Bottazzi,et al.  The Neglected Tropical Diseases of Latin America and the Caribbean: A Review of Disease Burden and Distribution and a Roadmap for Control and Elimination , 2008, PLoS neglected tropical diseases.

[37]  P. Leiva Faculty Opinions recommendation of Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. , 2008 .

[38]  J. Chiavetta,et al.  Assessment of a travel question to identify donors with risk of Trypanosoma cruzi: operational validity and field testing , 2008, Transfusion.

[39]  T. Garate,et al.  Transfusional chagas disease: parasitological and serological monitoring of an infected recipient and blood donor. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  Robert H Gilman,et al.  Evaluation and treatment of chagas disease in the United States: a systematic review. , 2007, JAMA.

[41]  G. Schmuñis Epidemiology of Chagas disease in non-endemic countries: the role of international migration. , 2007, Memorias do Instituto Oswaldo Cruz.

[42]  R. Goodrich,et al.  Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. , 2007, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[43]  S. Wagner,et al.  Photoinactivation of Trypanosoma cruzi in red cell suspensions with thiopyrylium. , 2007, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[44]  E. Peresi,et al.  Definition of a diagnostic routine in individuals with inconclusive serology for Chagas disease. , 2007, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[45]  L. Glasser,et al.  Transfusion‐acquired Trypanosoma cruzi infection , 2007, Transfusion.

[46]  M. Fresno,et al.  The efficacy of photochemical treatment with amotosalen HCl and ultraviolet A (INTERCEPT) for inactivation of Trypanosoma cruzi in pooled buffy‐coat platelets , 2007, Transfusion.

[47]  O. Garraud,et al.  Measures to prevent transfusion-associated protozoal infections in non-endemic countries. , 2007, Travel medicine and infectious disease.

[48]  M. Fresno,et al.  The efficacy of photochemical treatment with methylene blue and light for the reduction of Trypanosoma cruzi in infected plasma , 2006, Vox sanguinis.

[49]  L. Sawyer,et al.  Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function , 2006, Transfusion.

[50]  S. Trevethan,et al.  Blood transfusion and iatrogenic risks in Mexico City. Anti-Trypanosoma cruzi seroprevalence in 43,048 blood donors, evaluation of parasitemia, and electrocardiogram findings in seropositive. , 2005, Memorias do Instituto Oswaldo Cruz.

[51]  J. R. Cruz,et al.  Safety of the Blood Supply in Latin America , 2005, Clinical Microbiology Reviews.

[52]  E. Silveira-Lacerda,et al.  Chagas’ disease: application of TESA‐blot in inconclusive sera from a Brazilian blood bank , 2004, Vox sanguinis.

[53]  A. Farrugia The mantra of blood safety: time for a new tune? , 2004, Vox sanguinis.

[54]  W. V. Van Voorhis,et al.  Trypanosoma cruzi Inactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen HCl) and Long-Wavelength UV , 2003, Antimicrobial Agents and Chemotherapy.

[55]  Sergio L Vargas,et al.  Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the regression and prevention of electrocardiographic abnormalities during 9 years of follow-up , 2003, Annals of tropical medicine and parasitology.

[56]  C. Beard,et al.  Control of Chagas Disease. Second Report of the WHO Expert Committee. WHO Technical Report Series, No. 905. Geneva: World Health Organization, 2002. vi + 109pp. Price Sw.fr. 23/US$20.70 (in developing countries Sw.fr.16.10). ISBN 92-4-120905.4 , 2002 .

[57]  E. Chiari,et al.  Aminoquinolone WR6026 as a feasible substitute for gentian violet in Chagas' disease prophylaxis in preserved blood for transfusional purposes. , 2002, Revista da Sociedade Brasileira de Medicina Tropical.

[58]  J. Dias,et al.  The impact of Chagas disease control in Latin America: a review. , 2002, Memorias do Instituto Oswaldo Cruz.

[59]  M. Guariento,et al.  Use of a nested polymerase chain reaction (N-PCR) to detect Trypanosoma cruzi in blood samples from chronic chagasic patients and patients with doubtful serologies. , 2002, Diagnostic microbiology and infectious disease.

[60]  A Prata,et al.  Clinical and epidemiological aspects of Chagas disease. , 2001, The Lancet. Infectious diseases.

[61]  L. Corash,et al.  Inactivation of infectious pathogens in labile blood components: meeting the challenge. , 2001, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[62]  D. Leiby,et al.  Prospective evaluation of a patient with Trypanosoma cruzi infection transmitted by transfusion. , 1999, The New England journal of medicine.

[63]  S. Wendel Transfusion-transmitted Chagas' disease. , 1998, Current opinion in hematology.

[64]  J. Coura,et al.  Immunoblot assay using excreted-secreted antigens of Trypanosoma cruzi in serodiagnosis of congenital, acute, and chronic Chagas' disease , 1996, Journal of clinical microbiology.

[65]  L V Kirchhoff,et al.  American Trypanosomiasis (Chagas Disease) , 2018, Red Book (2018).

[66]  M. Blajchman,et al.  Prevention of transfusion‐associated Chagas' disease: efficacy of white cell‐reduction filters in removing Trypanosoma cruzi from infected blood , 1995, Transfusion.

[67]  E. Lages-Silva,et al.  Prevention of transfusion‐associated Chagas' disease by sterilization of Trypanosoma cruzi‐infected blood with gentian violet, ascorbic acid, and light , 1995, Transfusion.

[68]  A. Pan,et al.  Detection of antibodies to Trypanosoma cruzi among blood donors in the southwestern and western United States. II. Evaluation of a supplemental enzyme immunoassay and radioimmunoprecipitation assay for confirmation of seroreactivity , 1995, Transfusion.

[69]  S. Wendel Chagas Disease: An Old Entity in New Places , 1993, The International journal of artificial organs.

[70]  S. Wendel,et al.  Chagas' Disease and Blood Transfusion: A New World Problem? , 1993, Vox sanguinis.

[71]  L. Kirchhoff,et al.  Use of a questionnaire to identify potential blood donors at risk for infection with Trypanosoma cruzi , 1993, Transfusion.

[72]  G. Schmuñis Trypanosoma cruzi, the etiologic agent of Chagas' disease: status in the blood supply in endemic and nonendemic countries , 1991, Transfusion.

[73]  H. Tanowitz,et al.  Transfusion-associated acute Chagas disease acquired in the United States. , 1989, Annals of internal medicine.

[74]  R. Docampo,et al.  Enhancement of the cytotoxicity of crystal violet against Trypanosoma cruzi in the blood by ascorbate. , 1988, Molecular and biochemical parasitology.

[75]  H. Hendrickson Prevention of what? , 1983, Journal of the American Optometric Association.

[76]  J. Pruneda,et al.  [Chagas' disease and blood transfusion]. , 1972, Boletin de la Oficina Sanitaria Panamericana. Pan American Sanitary Bureau.

[77]  A. Trejos,et al.  [Strout's concentration method in the diagnosis of acute Chagas disease]. , 1966, Boletin chileno de parasitologia.

[78]  김성,et al.  Transmission , 1922, Sexistence.

[79]  M. Keenan,et al.  A new era for chagas disease drug discovery? , 2015, Progress in medicinal chemistry.

[80]  J. Rojo Medina [Blood Safety in the XXI century. Transfusion transmitted infectious diseases. International and Mexican view]. , 2014, Gaceta medica de Mexico.

[81]  O. Ritter,et al.  Epidemiology of Chagas disease in Europe: many calculations, little knowledge , 2013, Clinical Research in Cardiology.

[82]  Margaret Chan,et al.  Sustaining the drive to overcome the global impact of neglected tropical diseases : second WHO report on neglected tropical diseases , 2013 .

[83]  A. Assal,et al.  [Chagas disease and blood transfusion: an emerging issue in non-endemic countries]. , 2011, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[84]  T. Garate,et al.  [Comparison of conventional and non-conventional serological tests for the diagnosis of imported Chagas disease in Spain]. , 2010, Enfermedades infecciosas y microbiologia clinica.

[85]  R. López-Vélez,et al.  Chagas disease in a recipient of cord blood transplantation , 2007, Bone Marrow Transplantation.

[86]  P. Cimo,et al.  Transfusion-associated Chagas' disease in Texas: report of a case. , 1993, Texas medicine.

[87]  V. Amato Neto,et al.  [First tests on the accidental transmission of Chagas disease to man by blood transfusion]. , 1952, Revista paulista de medicina.